Anti-abortion group challenged during protest near Glasgow hospital
An anti-abortion group was challenged during a controversial protest near a Glasgow hospital.
Members of the 40 Days For Life group were branded 'disgusting' and accused of 'not caring about women' as they staged a vigil close to the Queen Elizabeth University Hospital.
They are planning a series of vigils from today until the middle of April, which includes holding 'choose life' signs and praying.
Despite being outside the 200-metre abortion buffer zone in place around the hospital's maternity unit, they remain visible on one of the main approaches to it on Shieldhall Road.
This caused outrage in the area with one woman, who has experienced of miscarriage, calling out the group after seeing the protest from her window.
READ MORE: 'Sick' criminals targeted four Glasgow primary schools within hours
El Johnstone (Image: PA)
El Johnstone told them: 'You should be ashamed of yourselves.'
Referring to the hospital, she said: 'You have no idea what the women there have gone through or are going through, you do not know.
'You have no respect for the women, you don't care about the women.'
Speaking to the media afterwards, Ms Johnstone, who has experience of miscarriage, said: 'I woke up this morning and went to have my breakfast and could see this from my bedroom window. I'm not receiving the healthcare and this has upset me so much.
'So imagine if you were going through a horrible, horrible decision in your life, and you're faced with this.
'You can pray in your church. You can pray in your houses. You do not need to come and pray outside a healthcare facility and upset everybody who's going there.
'I just have empathy for the people that do need access to services today, people who are going through something, people who might be miscarrying, like I have, and seeing this, it just adds to more stress and a horrible situation made worse.
'I just don't think it's necessary.'
El Johnstone (Image: PA)
I asked anti-abortion protesters what help they could actually offer me if I had an unwanted pregnancy. They had gathered close to the Queen Elizabeth University Hospital in Glasgow this morning. pic.twitter.com/pUMimZSm9q
— Kirsty Feerick (@KirstyFeerick) March 5, 2025
A reporter from the Glasgow Times also approached the group to ask what help they could actually offer as members held signs saying 'Pregnant? Support is available'.
However, they could not offer any on the spot support and instead handed over two phone numbers but no details.
When pushed for more context they insisted they had to get back to their prayers and shut down the conversation.
Meanwhile there were shouts of 'disgusting' from motorists driving past as the group continued to protest.
A woman holds a baby as she stands with Members of 40 Days for Life (Image: Jane Barlow)
Green MSP Gillian Mackay, who introduced the abortion buffer zone law which was passed last year, says it will face a 'real test' during the protests.
She said she will work with police and health authorities to ensure the Safe Access Zones Act is upheld.
In February, a 74-year-old woman became the first person in Scotland to be arrested over an alleged breach of the legislation.
Ms Mackay said: 'For far too long, women have had to endure totally unacceptable abuse and obstruction outside hospitals.
"It should never have happened, and my Act to stop it received the overwhelming support of our Parliament.
'I urge anyone else who is planning to protest to look at the testimonies from people who have had to endure gauntlets of graphic banners and ask themselves if they really want to be responsible for causing even more pain and upset.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scientific American
3 days ago
- Scientific American
Inside the Collapse of the America's Overdose Prevention Program
At an addiction conference in Nashville, Tenn., in late April, U.S. Secretary of Health and Human Services Robert F. Kennedy, Jr., spoke about his own experience with drug use. 'Addiction is a source of misery. It's also a symptom of misery,' he said. Kennedy's very personal speech, however, ignored recent federal budget cuts and staffing reductions that could undo national drug programs' recent progress in reversing overdoses and treating substance use. Several experts in the crowd, including Caleb Banta-Green, a research professor at the University of Washington, who studies addiction, furiously spoke up during Kennedy's speech. Banta-Green interrupted, shouting 'Believe science!' before being removed from the venue. (The Department of Health and Human Services did not respond to a request for comment for this article.) 'I had to stand up and say something,' says Banta-Green, who has spent his career working with people who use drugs and was a senior science adviser at the Office of National Drug Control Policy during the Obama administration. 'The general public needs to understand what is being dismantled and the very real impact it's going to have on them and their loved ones.' On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. The Trump administration has defunded public health programs and made plans to consolidate or eliminate the systems that track their outcomes, making it difficult to monitor the deadly consequences of substance use, Banta-Green says. For instance, staff cuts to the Overdose Data to Action program and the Opioid Overdose Prevention and Surveillance program will hamper former tracking efforts at the Centers for Disease Control and Prevention and at local and state health departments' prevention programs. A recently fired policy analyst at the overdose prevention division at the CDC's National Center for Injury Prevention and Control— who wishes to remain anonymous, citing fear of retaliation—tells Scientific American that she used to provide policy support to teams at health departments in 49 states and shared public overdose data and information to Congress. She is a veteran who should have had protected employment status, but she lost her job during federal cuts in February. 'No one else is doing surveillance and data collection and prevention like the CDC was,' she says. 'There's so much that's been cut.' (When approached for an interview by Scientific American, a CDC spokesperson said, 'Honestly, the new administration has changed how things normally work' and did not make anyone available for questions.) What Gets Measured Gets Managed Provisional data suggest that deaths from drug use declined by almost 25 percent in 2024, though overdoses remain the leading cause of death for Americans aged 18 to 44. Cuts to the National Survey on Drug Use and Health will make it difficult to measure similar statistics in the future. Because substance use is highly stigmatized, Banta-Green says it's important to have diverse, localized and timely data from multiple agencies to accurately capture the need for services—and the ways they're actually used. 'You can't design public health or policy responses if you don't know the scale of the need,' he says. Overdose trends vary by region—for example, usage of the synthetic opioid fentanyl appeared earlier on the East Coast than the West—so national averages can obscure critical local patterns. These regional differences can offer important insights into which interventions might be working, Banta-Green says. For instance, important medications such as naloxone rapidly reverse opioid overdoses in emergency situations. But getting people onto long-term medications, including methadone and buprenorphine, which reduce cravings and withdrawal symptoms, can more effectively prevent mortality in both the short and long term. Declining deaths may also mask tragic underlying dynamics. Successful interventions may not be the only cause of a drop in overdoses; it could also be that the people who are most vulnerable to overdose have recently perished and that there are simply fewer remaining at risk. 'It's like a forest fire burning itself out,' Banta-Green says. This underscores the need for the large-scale data collection threatened by the proposed budget and staff cuts at the CDC and National Institutes of Health, says Regina LaBelle, an addiction policy expert at Georgetown University. 'What [the administration is] doing is shortsighted' and doesn't appear to be based 'on the effectiveness or the outcomes of the programs that [it's] cutting,' she says. For example, despite promising to expand naloxone access, the Trump administration's latest budget proposal cuts funding for a critical program that distributes the lifesaving medication to first aid responders. 'A Chance at Redemption' When LaBelle was acting director of the White House Office of National Drug Control Policy during the Biden administration, she led efforts to expand evidence-based programs that provided clean syringes and tested users' drugs for harmful substances. These strategies are often referred to as 'harm reduction,' which LaBelle describes as 'a way you can meet people where they are and give them the services they need to keep them from dying.' José Martínez, a substance use counselor based in Buffalo, N.Y., says harm-reduction practices helped save his life. When Martínez got his first job as a peer advocate for people using drugs, he was still in a chaotic part of his own addiction and had been sleeping on the street and the subway—and regularly getting into fights—for a decade. The day after he was hired to help provide counseling on hepatitis C, he got into a New York City shelter. As his bruises healed, he learned life skills he was never taught at home. 'For a lot of people, drug use is a coping tool,' he says. 'The drug is rarely the problem. Drug use is really a symptom.' Working with others who understood that many people need help minimizing risks gave Martínez a chance to make progress toward recovery in a way that he says abstinence-only treatment programs couldn't. 'I don't agree that somebody should be sober in order for them to do things different,' he says. Over the past six years working for the National Harm Reduction Coalition, Martínez started a national support network for other peer program workers and community members—people who share their experiences and are a trusted source of education and support for others using drugs. 'There's never no time limit,' he says. 'Everybody works on their own pace.' Though Martínez's program doesn't take federal funding, the Trump administration is cutting similar kinds of peer programs. Martínez says doing this peer work gives many users a sense of purpose and stability—and helps them avoid previous behaviors. The proposed 2026 federal budget will slash the CDC's opioid surveillance programs by $30 million. It also creates a new subdivision called the Administration for a Healthy America that will consolidate the agency's prevention work, along with existing programs at the Substance Abuse and Mental Health Services Agency (SAMHSA), which often coordinates grants for treatment programs. The programs formerly conducted through SAMHSA are also facing cuts of more than $1 billion. Advocates fear this will include a shift toward funding abstinence-only priorities, which, Martínez says, 'will definitely mean that we're going to have more overdoses.' (Some research suggests abstinence-based treatment actually puts people at a higher risk of fatal overdose than those who receive no treatment at all.) 'The general public needs to understand what is being dismantled and the very real impact it's going to have on them and their loved ones.' —Caleb Banta-Green, addiction research professor These cuts could disproportionately affect communities already facing higher overdose rates: Martínez, who is Puerto Rican, notes that U.S. Black, Latino and Indigenous communities have experienced drug overdose death increases in recent years. In many states, overdose deaths in Black and brown communities remain high while white overdose death rates are declining. Looming cuts to Medicaid programs, LaBelle warns, are likely to worsen inequalities in health care access, which tends to make communities of color more vulnerable. In Kentucky, where Governor Andy Beshear recently celebrated a 30 percent decline in overdose deaths, Shreeta Waldon, executive director of the Kentucky Harm Reduction Coalition, says the reality is more nuanced. While national overdose deaths declined in white populations from 2021 to 2023, for example, they continued to rise among people of color. Black and Latino communities often face barriers when accessing health services, many of which have been shaped by predominantly white institutions. Waldon says it's essential for people from diverse backgrounds to participate in policy decisions and necessary to ensure that opioid abatement funds —legal funds used toward treatment and prevention—are distributed fairly. Without adequate federal funding, Waldon predicts treatment programs in Kentucky will become backlogged—potentially pushing more people into crisis situations that lead to emergency services or incarceration rather than to recovery. These financial and political pressures are not only making it harder to find support for people in crisis; they also reduce opportunities to discuss community needs. Waldon says she knows some social workers who now avoid terms such as 'Black woman' or 'marginalized' in grants and public talks out of fear of losing funding. But people currently needing treatment for substance-use disorder are not necessarily aware of the federal funding news—or 'what's about to hit them when they try to go get treatment and they're hit with barriers,' Waldon says. 'That's way more important to me than trying to tailor the way I talk.' Funding and staffing cuts don't just limit resources for the people most in need. They limit the ability to understand where someone is coming from, which undermines efforts to provide meaningful care, Martínez says. Harm reduction is more than the services and physical tools given to community members, he says. It's about the approach. 'When you look at a whole person, you plant the seed of health and dignity,' he says. 'If everybody deserves a chance at redemption, then we've got to rethink how we're approaching things.'
Epoch Times
3 days ago
- Epoch Times
Women Taking Weight-Loss Jabs Warned They Must Use Effective Contraception
Women taking weight-loss jabs are being warned they must use effective contraception. The Medicines and Healthcare products Regulatory Agency (MHRA) issued its first alert to the public regarding contraception and weight loss and diabetes jabs following concerns they may not be used safely. The injections have been previously linked to a 'baby boom,' with women reporting online that they have had surprise 'Ozempic babies' despite using contraception. To date, the MHRA has received more than 40 reports relating to pregnancy among women on the drugs. There are also warnings over a lack of evidence for pregnancy safety for the jabs, which include Ozempic, Mounjaro, Wegovy, Saxenda, and Victoza. The MHRA said the drugs—which are glucagon-like peptide-1 receptor agonists (GLP-1 or GLP-1 RAs)—must not be taken during pregnancy, while trying to get pregnant, or during breastfeeding. Related Stories 5/24/2025 2/21/2025 Anyone who gets pregnant while using the drugs should also stop taking the medicine, it added. It said, 'This is because there is not enough safety data to know whether taking the medicine could cause harm to the baby.' In some cases, women are also advised to continue using contraception for up to two months between stopping the medicine and trying to get pregnant. The MHRA said effective contraception includes the oral contraceptive pill, contraceptive implants, the coil, and condoms. Vials of Mounjaro in a box in a stock photo. Alamy/PA Those patients taking Mounjaro—which may reduce the effectiveness of oral contraceptives in people who are overweight—should also use condoms if they are on the pill. The MHRA said, 'This only applies to those taking Mounjaro and is especially important for the four weeks after starting Mounjaro and after any dose increase.' The advice on contraception is also contained in patient information leaflets that come with the medicines. MHRA data shared with the PA news agency show it has received 26 pregnancy-related reports for Mounjaro. It is not necessary for women to say whether the pregnancy was unintentional, though one report did say the pregnancy was such. There have been a further eight reports relating to pregnancy in people taking semaglutide (the ingredient in Ozempic and Wegovy). A further nine have been recorded for liraglutide (Victoza or Saxenda), of which one recorded the pregnancy was unintentional. The MHRA is also reminding people that weight-loss jabs should not be bought from unregulated sellers such as beauty salons or via social media, or taken without speaking to a health professional. Anyone who suspects they have had an adverse reaction or suspects their drug is not a genuine product, should report it to the MHRA Yellow Card scheme. Alison Cave, MHRA chief safety officer, said: 'Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments. 'They are not a quick fix to lose weight and have not been assessed to be safe when used in this way. 'Our guidance offers patients a 'one-stop shop' for our up-to-date advice on how to use these powerful medicines safely. 'This guidance should not be used as a substitute to reading the patient information leaflet or having a conversation with a healthcare professional as part of the prescribing process.' The injectable drug Ozempic in Houston on July 1, 2023. David J. Phillip/AP Photo The latest guidance also reminds patients taking jabs of the symptoms to look out for in the event of acute pancreatitis which, although uncommon, can be serious. The main symptom is severe pain in the stomach that radiates to the back and does not go away, and people should seek immediate medical help. GLP-1 or GLP-1 RAs help people feel fuller by mimicking a natural hormone released after eating. Some, like Mounjaro, also act on a second hormone involved in appetite and blood sugar control. Jasmine Shah, medication safety officer at the National Pharmacy Association, said: 'Pharmacists urge women taking GLP-1 medicines to note this important new guidance from the MHRA published today and use effective contraception. 'Community pharmacies have been experiencing unprecedented levels of interest for weight loss injections. 'It is therefore important that regulations and guidance keep pace with this demand and that patient safety is put at the heart of everything we do. 'Medicines are not like ordinary goods for sale; they must be handled with great care because they have the power to harm as well as to heal. 'We also reiterate warnings from the MHRA to avoid any potential fake weight loss injections sold on social media or via beauty salons, which could pose a serious risk to someone's health. 'We urge anyone who have concerns about this medication to speak to their pharmacist for advice.'
Yahoo
4 days ago
- Yahoo
Fears for safety of unborn babies after weight-loss jab alert
Pregnant women have been warned by the medical watchdog not to take weight-loss drugs as there is currently no guarantee there won't be any adverse affect on the baby. The Medicines and Healthcare products Regulatory Agency (MHRA) issued an alert over a lack of evidence for pregnancy safety for the jabs, which include Ozempic, Mounjaro, Wegovy, Saxenda and Victoza. The MHRA said the drugs – which are glucagon-like peptide-1 receptor agonists (GLP-1 or GLP-1 RAs) – must not be taken during pregnancy, while trying to get pregnant, or during breastfeeding. Anyone who gets pregnant while using the drugs should also stop taking the medicine, it added. It said: 'This is because there is not enough safety data to know whether taking the medicine could cause harm to the baby.' In some cases, women are also advised to continue using contraception for up to two months between stopping the medicine and trying to get pregnant. The MHRA said effective contraception includes the oral contraceptive pill, contraceptive implants, the coil and condoms. Those patients taking Mounjaro – which may reduce the effectiveness of oral contraceptives in people who are overweight – should also use condoms if they are on the Pill. The injections have been previously linked to a 'baby boom', with women reporting online that they have had surprise 'Ozempic babies' despite using contraception. To date, the MHRA has received more than 40 reports relating to pregnancy among women on the drugs. The MHRA said: 'This only applies to those taking Mounjaro and is especially important for the four weeks after starting Mounjaro and after any dose increase.' The advice on contraception is also contained in patient information leaflets that come with the medicines. MHRA data shared with by the PA news agency shows it has received 26 pregnancy-related reports for Mounjaro. It is not necessary for women to say whether the pregnancy was unintentional, though one report did say the pregnancy was such. There have been a further eight reports relating to pregnancy in people taking semaglutide (the ingredient in Ozempic and Wegovy). A further nine have been recorded for liraglutide (Victoza or Saxenda), of which one recorded the pregnancy was unintentional. The MHRA is also reminding people that weight-loss jabs should not be bought from unregulated sellers such as beauty salons or via social media, or taken without speaking to a health professional. Anyone who suspects they have had an adverse reaction or suspects their drug is not a genuine product, should report it to the MHRA Yellow Card scheme. Dr Alison Cave, MHRA chief safety officer, said: 'Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments. 'They are not a quick fix to lose weight and have not been assessed to be safe when used in this way. 'Our guidance offers patients a 'one-stop shop' for our up-to-date advice on how to use these powerful medicines safely. 'This guidance should not be used as a substitute to reading the patient information leaflet or having a conversation with a healthcare professional as part of the prescribing process.' The latest guidance also reminds patients taking jabs of the symptoms to look out for in the event of acute pancreatitis which, although uncommon, can be serious. The main symptom is severe pain in the stomach that radiates to the back and does not go away, and people should seek immediate medical help. GLP-1 or GLP-1 RAs help people feel fuller by mimicking a natural hormone released after eating. Some, like Mounjaro, also act on a second hormone involved in appetite and blood sugar control. Jasmine Shah, medication safety officer at the National Pharmacy Association, said: 'Pharmacists urge women taking GLP-1 medicines to note this important new guidance from the MHRA published today and use effective contraception. 'Community pharmacies have been experiencing unprecedented levels of interest for weight-loss injections. 'It is therefore important that regulations and guidance keep pace with this demand and that patient safety is put at the heart of everything we do. 'Medicines are not like ordinary goods for sale; they must be handled with great care because they have the power to harm as well as to heal. 'We also reiterate warnings from the MHRA to avoid any potential fake weight loss injections sold on social media or via beauty salons, which could pose a serious risk to someone's health. 'We urge anyone who have concerns about this medication to speak to their pharmacist for advice.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
